Results 61 to 70 of about 2,896 (157)

Targeting cholesterol metabolism to overcome Zanubrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma

open access: yesMedicine in Novel Technology and Devices
Bruton tyrosine kinase (BTK) inhibitor Zanubrutinib shows considerable potential for treating activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL). However, its efficacy is often limited by unresolved resistance mechanisms.
Zhuojun Liu   +9 more
doaj   +1 more source

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp   +5 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Association between patient-reported symptoms and clinical outcomes in R/R CLL

open access: yesBlood Advances
: The ALPINE trial was a randomized, open-label study comparing the efficacy and safety of zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Using patient-
Timothy Victor   +9 more
doaj   +1 more source

A Systematic Intracranial Exposure‐Response Evaluation of Brain‐Penetrant Inhibitors: Informing Dose Selection for Brain Metastases

open access: yesClinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT Brain metastases (BMs) represent a major clinical challenge due to their high incidence in cancers such as non‐small cell lung cancer (NSCLC) and breast cancer, and the limited efficacy of systemic therapies resulting from inadequate drug penetration across the blood–brain barrier.
Yuqian Zhao, Weize Huang
wiley   +1 more source

Establishment and Validation of a UPLC-MS/MS Method for Quantitative Determination of Zanubrutinib and Posaconazole in Rat Plasma: Application in Drug–Drug Interaction Studies

open access: yesDrug Design, Development and Therapy
Hailun Xia,1 Yuxin Shen,1,2 Xinhao Xu,1,2 Jun Wu,1,2 Guanyang Lin,1,2 Xiaoxiang Du1 1Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2School of Pharmaceutical Sciences ...
Xia H, Shen Y, Xu X, Wu J, Lin G, Du X
doaj  

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders

open access: yesPharmacological Research
The Bruton nonreceptor protein-tyrosine kinase (BTK) plays a central role in B cell antigen receptor signaling. Following B cell receptor activation, the Src protein kinase Lyn and the spleen protein kinase (Syk) activate BTK.
Robert Roskoski, Jr
doaj   +1 more source

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors

open access: yes
Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco   +4 more
wiley   +1 more source

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

open access: yesBlood Advances
: Some patients with chronic lymphocytic leukemia who develop progressive disease (PD) during covalent Bruton tyrosine kinase (BTK) inhibitor treatment acquire resistance mutations in BTK or PLCG2.
Jennifer R. Brown   +12 more
doaj   +1 more source

Zanubrutinib in the treatment of Waldenström Macroglobulinemia

open access: yesFuture Oncology
Waldenström Macroglobulinemia (WM) is an uncommon malignancy of IgM-secreting lymphoplasmacytic cells. The spectrum of acquired somatic mutations is heterogeneous, with MYD88 mutations occurring in more than 90%. Recurrent mutations in CXCR4, KMT2D, ARID1A, TERT, and TP53 are also detected, with some of these impacting prognosis or treatment response ...
Elizabeth Goodall, Stephen Opat
openaire   +3 more sources

Home - About - Disclaimer - Privacy